SCHEDULE 13G/A: CVI Investments and Heights Capital Management Disclose 4.9% Passive Stake in Bionano Genomics
Beneficial Ownership Report (Schedule 13G Amendment)
CVI Investments, Inc. and Heights Capital Management, Inc. have jointly filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.9% in Bionano Genomics, Inc. as of March 31, 2025.
Summary
- CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, 'Reporting Persons') have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Bionano Genomics, Inc.
- As of March 31, 2025, the Reporting Persons collectively beneficially own 157,930 shares of Bionano Genomics, Inc. common stock.
- This ownership represents 4.9% of the company's outstanding common stock.
- The beneficially owned shares consist of common stock issuable upon the exercise of warrants.
- The warrants are structured with a limitation, preventing their exercise if it would result in the Reporting Persons' beneficial ownership exceeding 4.99% of the outstanding shares.
- Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and holds shared voting and dispositive power over the reported shares.
- Bionano Genomics, Inc. had 3,007,000 shares outstanding as of March 24, 2025, as disclosed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment towards the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a passive investment stake by institutional investors in a publicly traded company within the biotechnology or genomics sector. It does not provide broader industry trends but indicates continued institutional interest in Bionano Genomics.
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding a significant passive ownership stake by institutional investors, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/24/2025 | Date as of which Bionano Genomics, Inc. had 3,007,000 shares outstanding, as reported in their 10-K. |
| 03/31/2025 | Date of event which required the filing of this Schedule 13G amendment. |
| 05/12/2025 | Date of signature for the Schedule 13G filing. |
Keywords
Bionano Genomics, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.